As of 2024-12-12, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -10.62 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 16.5x | 15.0x |
| Forward P/E multiples | 15.0x - 17.7x | 15.8x |
| Fair Price | (53.01) - (58.08) | (54.12) |
| Upside | -21747.1% - -23815.6% | -22198.7% |
| Date | EV/EBITDA |
| 2024-12-11 | 0.11 |
| 2024-12-10 | 0.11 |
| 2024-12-09 | 0.11 |
| 2024-12-06 | 0.11 |
| 2024-12-05 | 0.11 |
| 2024-12-04 | 0.11 |
| 2024-12-03 | 0.11 |
| 2024-12-02 | 0.11 |
| 2024-11-29 | 0.10 |
| 2024-11-27 | 0.10 |
| 2024-11-26 | 0.11 |
| 2024-11-25 | 0.11 |
| 2024-11-22 | 0.10 |
| 2024-11-21 | 0.11 |
| 2024-11-20 | 0.10 |
| 2024-11-19 | 0.10 |
| 2024-11-18 | 0.12 |
| 2024-11-15 | 0.11 |
| 2024-11-14 | 0.10 |
| 2024-11-13 | 0.08 |
| 2024-11-12 | -0.59 |
| 2024-11-11 | -0.73 |
| 2024-11-08 | -0.55 |
| 2024-11-07 | -0.54 |
| 2024-11-06 | -0.51 |
| 2024-11-05 | -0.53 |
| 2024-11-04 | -0.50 |
| 2024-11-01 | -0.46 |
| 2024-10-31 | -0.53 |
| 2024-10-30 | -0.52 |
| 2024-10-29 | -0.53 |
| 2024-10-28 | -0.41 |
| 2024-10-25 | -0.38 |
| 2024-10-24 | -0.40 |
| 2024-10-23 | -0.45 |
| 2024-10-22 | -0.51 |
| 2024-10-21 | -0.45 |
| 2024-10-18 | -0.37 |
| 2024-10-17 | -0.37 |
| 2024-10-16 | -0.36 |
| 2024-10-15 | -0.38 |
| 2024-10-14 | -0.37 |
| 2024-10-11 | -0.36 |
| 2024-10-10 | -0.37 |
| 2024-10-09 | -0.37 |
| 2024-10-08 | -0.38 |
| 2024-10-07 | -0.36 |
| 2024-10-04 | -0.37 |
| 2024-10-03 | -0.36 |
| 2024-10-02 | -0.36 |